利巴韦林治疗TTV型肝炎的疗效观察

目的:观察利巴韦林治疗TTV型肝炎的临床疗效。方法:收集40例TTV型肝炎患者,随机分成治疗组和对照组各20例;治疗组:利巴韦林150mg/次,3次/d×3月;对照组:常规护肝治疗。结果:治疗1个月后,对照组:ALT、AST复常率20％,TTV DNA转阴率0％,治疗组:ALT、AST复常率达60％,TTV DNA转阴率达50％。治疗2个月后,对照组:ALT、AST复常率30％,TTV DNA0％;治疗组:ALT、AST复常率达80.0％,TTV DNA阴转率达75％,治疗3个月后,对照组:ALT、AST复常率40％,TTV DNA阴转率0％;治疗组;ALT、AST复常率达90%,TTV DNA阴转率90%。两组治疗前后比较,差异显著(P<0.05)。结论:利巴韦林治疗TTV型肝炎有较好的改善患者的肝功能和使TTV DNA转阴的作用。

利巴韦林治疗TTV型肝炎的疗效观察

目的 观察利巴韦林治疗TTV型肝炎的临床疗效。方法 采集 40例TTV型肝炎患者 ,随机分成治疗组和对照组各 2 0例。治疗组 :利巴韦林 15 0mg/次 ,3次 /d× 3月 ;对照组 :常规护肝治疗。结果 治疗 1个月后 ,对照组ALT、AST复常率 2 0 %,TTVDNA转阴率 0 %;治疗组ALT、SAT复常率达 60 %,TTVDNA转阴率达 5 0 %。治疗 2个月后 ,对照组ALT、ADT复常率 3 0 %,TTVDNA转阴率 0 %;治疗组ALT、AST复常率达 80 0 %,TTVDNA阴转率达 75 %。治疗 3个月后 ,对照组ALT、AST复常率 40 %、TTVDNA阴转率 0 %;治疗组ALT、AST复常率达 90 %,TTVDNA阴转率 90 %。两组治疗前后比较 ,差异显著 (P <0 0 5 )。结论 利巴韦林治疗TTV型肝炎有较好的改善患者的肝功能和使TTVDNA阴转的作用。

某部新兵TT病毒感染情况的研究

目的 :了解部队 1999年入伍新兵TT病毒 (TTV)感染情况 ,为部队做好TTV感染的防治工作提供依据。方法 :采用巢式PCR方法 ,对驻闽南某部 2 51名 1999年入伍新兵血清进行TTV -DNA检测 ,同时做抗HAV -lgM、HBV -M、HCV -RNA、抗HEV -IgG和肝功能检查。对TTV感染者和肝功能异常者进行重点体检和流行病学调查。结果 :在 2 51名被检的新兵中 ,发现TTV感染者 19例 ( 7.5% ) ,其中福建、江西、江苏、山东和河南籍新兵分别为 4例 ( 8.0 0 % )、2例( 5.13% )、6例 ( 8.82 % )、6例 ( 7.89% )和 1例 ( 5.56% ) ;来自农村 10例新兵阳性感染率为 5.2 9%( 10 / 189)、城市为 14.5% ( 9/ 62 ,P <0 .0 5)。TTV感染者均无乏力、纳差、肝脾肿大等肝炎的症状体征。结论 :某部 1999年入伍新兵中存在TTV感染 ,均为健康携带者 ;TTV感染率五省籍新兵无显著差异 (P >0 .0 5) ,来自城市新兵显著高于农村新兵 (P <0 .0 5)。

Coinfection of TT virus and response to interferon therapy in patients with chronic hepatitis B or C

AIM: To investigate the serum positive percentage of TT virus (TTV) in patients with chronic hepatitis B or C and the response of the coinfected TTV to interferon (IFN) during IFN therapy for chronic hepatitis B and C. METHODS: We retrospectively studied the serum samples of 70 patients with chronic hepatitis who had received IFN-alpha therapy from January 1997 to June 2000, which included 40 cases of hepatitis B and 30 hepatitis C. All the patients had been followed up for at least 6 months after the end of IFN therapy. The serum TTV DNA was detected using the polymerase chain reaction (PCR) before and every month during the course of IFN treatment. RESULTS: TTV infection was detected in 15% (6/40) of the chronic hepatitis B group and 30% (9/30) of the chronic hepatitis C group. Loss of serum TTV DNA during IFN therapy occurred in 3 of 6 patients (50%) and 6 of 9 (67%) of hepatitis B and C groups, respectively. Seronegativity of TTV was found all during the first month of IFN therapy in the 9 patients. There was no correlation between the seroconversion of TTV and the biochemical changes of the patients. CONCLUSION: TTV is not infrequently coinfected in patients with chronic hepatitis B and C in Taiwan, and more than half of the TTV infections are IFN-sensitive. However, the loss of serum TTV DNA does not affect the clinical course of the patients with chronic hepatitis B or C.